Acorda Therapeutics Completes $11.5 Million Private Financing.Business Editors/Health/Medical Writers HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 4, 2004 Acorda Therapeutics announced today that it has raised $11.5 million in a private financing comprising new and existing institutional investors. Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. (SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. ), multiple sclerosis (MS) and related central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 trials for MS. Acorda's technology platform also includes valrocemide, which is in clinical development for the treatment of epilepsy and bipolar disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. . Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion